Now that the Brexit transition is over and we can look back, what was the cost to the pharma industry as a result of Brexit and the difficulties with the supply of safe and compliant medicines?
Brexit has cost the industry a lot in terms of hours and money. Resources that could have been spent on innovation and strengthening compliance and cooperation across the block; were instead diverted to Brexit planning and risk mitigation. Supply of medicines has not been disrupted as a result of the combined effort and cooperation between the MHRA, EMA and competent authorities in other EU member states.
Read our article: The impact of Brexit on the movement of medicines